Knowledge centre

Medical news

Regulatory approvals, guideline updates and safety notices, summarised without hype and with the underlying evidence named.

Regulation · 5 min read

How to read a new drug approval headline

Approval by the MHRA, EMA or FDA means the regulator judged benefit to outweigh risk for a defined indication and population — not that the drug is suitable for everyone with the condition.

Marketing authorisation always specifies an indication, a line of therapy and often a biomarker requirement. A drug approved for second-line treatment in PD-L1 positive disease is not approved for first-line use in unselected patients.

Approval and funding are separate. In the UK, NICE or the SMC assess cost-effectiveness after regulatory approval, and local availability may lag by months.

Look for the primary endpoint. Overall survival is the most robust outcome; progression-free survival and response rate are surrogate endpoints that do not always translate into longer life.

Guidelines · 4 min read

Guideline updates and what they mean for existing patients

When a guideline changes, patients already on treatment are not automatically switched. Continuity, tolerance and response to current therapy are weighed against the new recommendation.

Guideline bodies such as NICE, ESMO, ESC and the ADA revise recommendations as trial data matures. A change in first-line recommendation applies primarily to patients starting treatment.

If you are stable and tolerating current therapy, switching may carry more risk than benefit. This is a reasonable question to raise at review and a common trigger for an independent opinion.

These articles are general education reviewed by our clinical editorial team. They are not tailored to your circumstances and do not constitute medical advice, diagnosis or a recommendation to start, stop or change any treatment.